Date:2/17/2009

th Chicago, IL facilities as part of Hospira's facilities optimization initiatives; Mayne Pharma integration charges of $0.9; and intangible asset impairment of $7.5 related to a non-strategic device product. F -- Other acquisition-related (charge) refund: refund of bridge loan fees incurred as a result of the Mayne Pharma acquisition expensed upon refinancing of loan during the first quarter of 2007. G -- Acquired in-process research and development. nm = Percent change is not meaningful. Hospira, Inc. Reconciliation of Condensed Consolidated Statements of Income (Unaudited) (dollars and shares in millions, except per share amounts) Years Ended December 31, --------------------------------------------------------- 2008 2007 ---------------------------- --------------------------- GAAP Adjustments Adjusted GAAP Adjustments Adjusted -------- ----- ------- ------- ------ ------- Net sales $3,629.5 $ - $3,629.5 $3,436.2 $ - $3,436.2 Cost of products sold 2,307.5 (104.5)A 2,203.0 2,262.3 (151.2)F 2,111.1 -------- ----- ------- ------- ------ ------- Gross Profit 1,322.0 104.5 1,426.5 1,173.9 151.2 1,325.1 Research and development 213.6 (3.3)B 210.3 201.2 (1.6)D 199.6 Acquired in-process research and development 0.5 (0.5)C - 88.0 (88.0)C - Selling, general and administrative 590.1 (21.0)D 569.1 582.1 (36.2)D 545.9 -------- ----- ------- ------- ------ -------
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine news :

1. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
2. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
3. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
4. Hospira Names Ken Meyers to Lead Human Resources
5. Hospira Reports Third-Quarter 2008 Results
6. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
7. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
8. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
9. Hospira Reports Second-Quarter 2008 Results
10. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
11. Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders